Phase II Study of Radioimmunotherapy With Zevalin (Ibritumomab Tiuxetan) Therapy for Patients With Refractory or Relapsed Primary Central Nervous System Lymphoma (PCNSL)
Phase of Trial: Phase II
Latest Information Update: 22 Jul 2018
Price : $35 *
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Rituximab
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 17 Jun 2015 Status changed from suspended to discontinued,as reported by ClinicalTrials.gov
- 24 Mar 2015 Status changed from recruiting to suspended, as reported by ClinicalTrials.gov record.
- 01 Dec 2014 Planned End Date changed from 1 Jul 2015 to 1 Jul 2016 as reported by ClinicalTrials.gov record.